|
|
|
|
| LEADER |
01459nam a2200253 u 4500 |
| 001 |
EB002001026 |
| 003 |
EBX01000000000000001163927 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Clinical review report: Tafamidis (Vyndaqel) (Pfizer Canada ULC)
|h Elektronische Ressource
|b indication: for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild-type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization
|
| 246 |
3 |
1 |
|a Clinical review report for Tafamidis (Vyndaqel)
|
| 246 |
3 |
1 |
|a Tafamidis (Vyndaqel) (Pfizer Canada ULC)
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, April 2020
|
| 300 |
|
|
|a 1 PDF file (80 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Final (with redactions)."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK563057
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective of this report was to perform a systematic review of the beneficial and harmful effects of tafamidis meglumine 80 mg for the treatment of adult patients with cardiomyopathy due to wild-type or hereditary transthyretin-mediated amyloidosis (hATTR)
|